| Clinical data | |
|---|---|
| Trade names | Amvuttra |
| Other names | ALN-65492 |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | Subcutaneous |
| Legal status | |
| Legal status | |
Vutrisiran, sold under the brand name Amvuttra, is a medication used to treat polyneuropathy in hereditary transthyretin-mediated (hATTR) amyloidosis.[1] It is used in adults who are still able to walk.[2] It is used by injection under the skin.[1]
Common side effects include joint pain, shortness of breath, and vitamin A deficiency.[1] Vitamin A supplements are recommended.[1] It is a small interfering RNA (siRNA) that decreases expression of the transthyretin (TTR) gene.[1][3]
Vutrisiran was approved for medical use in the United States and Europe in 2022.[1][2] In the United States it costs about 244,000 USD per dose.[4] It is made by Alnylam Pharmaceuticals.[5]
References
edit- ^ a b c d e f g h i "Amvuttra- vutrisiran injection". DailyMed. 21 June 2022. Archived from the original on 3 July 2022. Retrieved 3 July 2022.
- ^ a b c d "Amvuttra EPAR". European Medicines Agency. 18 July 2022. Archived from the original on 13 October 2022. Retrieved 13 October 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ Aimo A, Castiglione V, Rapezzi C, Franzini M, Panichella G, Vergaro G, Gillmore J, Fontana M, Passino C, Emdin M (March 2022). "RNA-targeting and gene editing therapies for transthyretin amyloidosis". Nature Reviews. Cardiology. doi:10.1038/s41569-022-00683-z. PMID 35322226. S2CID 247623259.
- ^ "Amvuttra Prices, Coupons, Copay & Patient Assistance". Drugs.com. Archived from the original on 8 September 2022. Retrieved 12 December 2022.
- ^ "Vutrisiran". SPS - Specialist Pharmacy Service. 11 January 2021. Archived from the original on 14 October 2022. Retrieved 13 December 2022.